OR2T1

Across TCGA pan-cancer cohorts, OR2T1 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR2T1 data layer compared with 6 for mutation status.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher OR2T1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T1 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

PAAD, STAD, and READ are the cancer types where OR2T1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.161	0.645	<.001	36	view →
STAD	DFS	Tertile	All	0.389	0.728	.004	33	view →
READ	DFS	Tertile	IV	0.255	0.628	.020	27	view →
BLCA	DFS	Tertile	III,IV	0.196	0.574	.025	18	view →
PRAD	DFS	Tertile	All	0.401	0.818	<.001	18	view →
LIHC	OS	Tertile	All	0.292	0.679	.020	9	view →
ESCA	OS	Tertile	III,IV	0.852	0.376	.044	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR2T1–PAAD (OS)

Open the PAAD breakdown →